In dogs diagnosed with osteoarthritis, how safe and effective is long-term treatment with bedinvetmab in providing analgesia?

There is an erratum to this paper published in Veterinary Evidence Vol 8, Issue 3 (2023): https://doi.org/10.18849/ve.v8i3.668. PICO question: In dogs diagnosed with osteoarthritis (OA), how safe is treatment with bedinvetmab, when compared to a placebo and how effective in long-term reduction of the severity of the clinical signs associated with OA-related pain? Clinical bottom line: Category of research: Treatment. Number and type of study designs reviewed: Two papers were critically reviewed. One was a randomised, blinded, multi-arm laboratory safety study; the other a multi-center field trial consisting of a block-randomised, double blind, placebo-controlled phase, followed by a non-comparative, open-label case series study. Strength of evidence: Weak. Outcomes reported: One study rated the reduction of the severity of clinical signs associated with OA pain using owner Canine Brief Pain Inventory (CBPI) ratings and non-validated veterinary clinical assessments (VCAs). Safety was addressed by evaluating adverse health effects (AHEs), concentration of antidrug antibodies (ADAs), and clinical pathology. Significant improvements in pain scores and VCAs were reported in this treatment study. The second safety-only study used clinical observation to evaluate AHEs. Both studies reported AHEs. Conclusion: The quality of the published evidence available to answer the PICO question 'In dogs diagnosed with osteoarthritis, how safe and effective is long-term treatment with bedinvetmab in providing analgesia' is weak due to design limitations of the two studies so far published. The decision to use bedinvetmab remains dependent on the judgement and experience of the clinician.